Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen receives European approval for Prolia

Amgen receives European approval for Prolia

1st June 2010

Amgen has announced that European marketing authorisation has been granted for Prolia, a new bone disease treatment for men and women in certain at-risk groups.

The drug is designed to prevent fractures among postmenopausal women with osteoporosis, as well as being the first available treatment in Europe for preventing bone loss associated with hormone ablation in men with prostate cancer.

This decision represents the first regulatory approval granted to the Amgen/GlaxoSmithKline treatment, which has demonstrated its safety and efficacy in a number of clinical trials.

Will Dere, senior vice-president and international chief medical officer at Amgen, said: “Prolia reduces the risk of fracture through a convenient injection given every six months. Amgen is proud to make this new treatment available to physicians and their patients.”

Later this week, the pharmaceutical company will be attending the 2010 American Society of Clinical Oncology annual meeting, where it will present new clinical trial data on innovative cancer drugs.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.